Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxford COVID-19 vaccine trial
ISRCTN90906759Phase 3Completed
- Sponsor
- University of Oxford
- Start
- May 2020
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Oxford. Primary endpoints: Efficacy against symptomatic COVID-19 and Serious adverse events. Started May 2020; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN90906759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90906759.